FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Tegsedi, inotersen, is an ‘antisense oligonucleotide', a very short piece of synthetic genetic material that has been designed to attach to and block the genetic material of the cell responsible for producing transthyretin.
Croatian: Djelatna tvar u lijeku Tegsedi, inotersen, je antisens oligonukleotid, vrlo kratak sintetički genski materijal koji je namijenjen za vezivanje na genski materijal stanica odgovornih za stvaranje transtiretina, i njegovo blokiranje.
English: As for all medicines, data on the use of Tegsedi are continuously monitored.
Croatian: Kao za sve lijekove, podaci o primjeni lijeka Tegsedi kontinuirano se prate.
English: Tegsedi must not be used by patients with low platelet counts (less than 100x109/l), and by patients with severe kidney or liver problems.
Croatian: Lijek Tegsedi ne smije se primjenjivati u bolesnika s niskim brojem trombocita (manje od 100x109/l) ni u bolesnika koji imaju teška oštećenja bubrega ili jetre.
English: Quality of life, measured by the Norfolk QoL-DN score, worsened by around 4 points in patients treated with Tegsedi, compared with around 13 points in those on placebo.
Croatian: Kvaliteta života, mjerena rezultatima na ljestvici Norfolk QoL-DN, pogoršala se za otprilike četiri boda u bolesnika liječenih lijekom Tegsedi, u usporedbi s otprilike 13 bodova u bolesnika koji su primali placebo.
English: Tegsedi is a medicine used to treat nerve damage caused by hereditary transthyretin amyloidosis (hATTR), a disease in which proteins called amyloids build up in tissues around the body including around the nerves.
Croatian: Tegsedi je lijek koji se primjenjuje za liječenje oštećenja živaca koja su uzrokovana nasljednom transtiretinskom amiloidozom (hATTR), bolešću pri kojoj se proteini naziva amiloidi nakupljaju u tkivu u tijelu, uključujući i oko živaca.
English: After 15 months of treatment, the mNIS+7 score, used for assessing nerve damage, worsened by a lesser extent with Tegsedi (around 11 points) than with placebo (around 25 points).
Croatian: Nakon 15 mjeseci liječenja, rezultati prema ljestvici mNIS+7 koja se upotrebljavala za procjenu oštećenja živaca, pogoršali su se u manjoj mjeri pri primjeni lijeka Tegsedi (otprilike 11 bodova) u odnosu na placebo (otprilike 25 bodova).
English: As Tegsedi can cause a reduction in the number of platelets in the blood (posing a risk of bleeding), blood platelet counts need to be monitored during treatment with Tegsedi, and the dose of the medicine and how often it is given adjusted accordingly.
Croatian: Budući da Tegsedi može prouzročiti smanjenje broja trombocita u krvi (predstavlja rizik od krvarenja) potrebno je kontrolirati broj trombocita u krvi tijekom liječenja lijekom Tegsedi, te sukladno tome prilagoditi dozu lijeka i učestalost primjene.
English: hATTR is rare, and Tegsedi was designated an ‘orphan medicine' (a medicine used in rare diseases) on 26 March 2014.
Croatian: Nasljedna transtiretinska amiloidoza je rijetka bolest, a Tegsedi je dobio status „lijeka za liječenje rijetkih bolesti” od 26. ožujka 2014.
English: The company that markets Tegsedi will provide an alert card for patients with information about the safety of the medicine and how to manage side effects.
Croatian: Tvrtka koja stavlja lijek Tegsedi u promet osigurat će karticu s upozorenjima za bolesnike s informacijama o sigurnosti lijeka i kontroli nuspojava.
English: In patients with hATTR, a protein called transthyretin which circulates in the blood is defective and breaks easily.
Croatian: U bolesnika s nasljednom transtiretinskom amiloidozom, protein naziva transtiretin koji cirkulira u krvi oštećen je i lako se raspada.
English: In one main study involving 173 hATTR patients with stage 1 or 2 nerve damage, Tegsedi was shown to be more effective than placebo (a dummy treatment) at slowing down the nerve damage caused by the disease.
Croatian: U jednom glavnom ispitivanju koje je obuhvatilo 173 bolesnika s nasljednom transtiretinskom amiloidozom koji su imali 1. stadij ili 2. stadij oštećenja živaca lijek Tegsedi pokazao se djelotvornijim od placeba (prividno liječenje) u usporavanju oštećenja živaca koja ta bolest uzrokuje.
English: Tegsedi was shown to be effective in the treatment of stage 1 or stage 2 nerve damage in patients with hATTR; available data were not sufficient to assume a beneficial effect in stage 3 patients (those confined to a wheelchair).
Croatian: Lijek Tegsedi pokazao se djelotvornim u liječenju bolesnika s nasljednom transtiretinskom amiloidozom koji imaju 1. stadij ili 2. stadij oštećenja živaca; dostupni podaci nisu dostatni da bi se pretpostavio povoljan učinak u bolesnika u 3. stadiju (koji su vezani za invalidska kolica).
English: Tegsedi can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of patients with hATTR.
Croatian: Lijek Tegsedi izdaje se samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju bolesnika s nasljednom transtiretinskom amiloidozom.
English: What benefits of Tegsedi have been shown in studies?
Croatian: Koje su koristi lijeka Tegsedi dokazane u ispitivanjima?
English: Other information about Tegsedi
Croatian: Ostale informacije o lijeku Tegsedi
English: For the full list of side effects of Tegsedi, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Tegsedi potražite u uputi o lijeku.
English: See section 4 for more information.
Croatian: Pogledajte dio 4. za dodatne informacije.
English: Date of latest renewal: 11 September 2014
Croatian: Datum posljednje obnove odobrenja: 11. rujna 2014.
English: mannitol, lactitol or maltitol), if taken regularly.
Croatian: manitola, laktitola ili maltitola), ako se uzimaju redovito
English: Very rare: Peripheral neuropathy (or paraesthesia).
Croatian: Vrlo rijetko: periferna neuropatija (ili parestezije).
English: If you notice any of these symptoms: Tell your doctor.
Croatian: Ako primijetite neki od tih simptoma: obavijestite svog liječnika.
English: For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder
Croatian: Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet
English: Following oral administration, the mean time (tmax) to maximal serum concentrations (Cmax) is about an hour.
Croatian: Nakon oralne primjene, srednje vrijeme (tmax) do maksimalne serumske koncentracije (Cmax) iznosi oko jedan sat.
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines or other medicines you bought without a prescription.
Croatian: Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i biljne lijekove ili lijekove koji se mogu nabaviti bez recepta.
English: If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Croatian: Ukoliko primjetite bilo koji simptome infekcije ili druge simptome kao što su mišićna slabost, slabost koja počinje u rukama i nogama i kreće se prema trupu tijela, lupanje srca, tremor ili hiperaktivnost, javite se odmah svom liječniku kako bi dobili potrebno liječenje.
English: Talk to your doctor if this applies to you or your child.
Croatian: Razgovarajte sa svojim liječnikom ako se to odnosi na Vas ili vaše dijete.
English: • if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection,
Croatian: • ako ste ikad imali neku bolest jetre, uključujući hepatitis B ili C (ako imate infekciju hepatitisom B,
English: Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (<4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age.
Croatian: Na temelju više od 200 parova majka/dijete liječenih zbog HIV infekcije, serumske koncentracije lamivudina u dojenčadi čije su majke liječene zbog HIV infekcije su vrlo niske (< 4% serumskih koncentracija u majke) i progresivno se smanjuju do nemjerljivih razina nakon što dojenče navrši 24 tjedna.
English: Administration of crushed tablets with a small amount of semi-solid food or liquid would not be expected to have an impact on the pharmaceutical quality, and would therefore not be expected to alter the clinical effect.
Croatian: Primjena zdrobljene tablete s manjom količinom kašaste hrane ili tekućine ne bi trebala utjecati na farmakološku kvalitetu, pa se ne očekuje niti promjena kliničkog učinka.
English: Children (weighing less than 25 kg)
Croatian: Djeca (tjelesne težine manje od 25 kg)
English: As doses below 150 mg are needed the use of an oral solution is recommended
Croatian: Budući da su potrebne doze manje od 150 mg, preporučuje se primjena oralne otopine
English: If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered (see section 4.8).
Croatian: Ako postoje dokazi o pogoršanju oboljenja jetre u tih bolesnika, treba razmotriti privremeni ili trajni prekid liječenja (vidjeti dio 4.8).
English: • if you are allergic to lamivudine or any of the other ingredients of this medicine (listed in section 6).
Croatian: • ako ste alergični na lamivudin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: Rare: Pancreatitis, elevations in serum amylase.
Croatian: Rijetko: pankreatitis, povišene razine serumskih amilaza.
English: CD4 cells are a type of white blood cells, that are important in helping your body to fight infection.
Croatian: CD4 stanice su vrsta bijelih krvnih stanica koje imaju važnu ulogu u pružanju podrške organizmu u obrani od infekcija.
English: Pharmacotherapeutic group: nucleoside analogue, ATC Code: J05AF05.
Croatian: Farmakoterapijska skupina: analog nukleozida, ATK oznaka: J05AF05.
English: Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85%.
Croatian: Apsorpcija Lamivudin se dobro apsorbira iz gastrointestinalnog trakta, a bioraspoloživost peroralno primijenjenog lamivudina u odraslih normalno je između 80 i 85%.
English: A modest increase in Cmax (28%) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) is not significantly altered.
Croatian: Zabilježen je umjeren porast Cmax (28%) zidovudina pri istodobnoj primjeni s lamivudinom, ali se ukupna izloženost (AUC) nije značajno promijenila.
English: If you are breast-feeding, or thinking about breast-feeding: Talk to your doctor immediately.
Croatian: Ako dojite ili razmišljate o dojenju: odmah se javite svojem liječniku.
English: If you have taken Lamivudine Teva Pharma B.V. during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.
Croatian: Ako ste Lamivudin Teva Pharma B.V. uzimali tijekom trudnoće, postoji mogućnost da liječnik zatraži redovito provođenje pretraga krvi i drugih dijagnostičkih pretraga kako bi pratio razvoj Vašeg djeteta.
English: Check with your doctor if you think this applies to you.
Croatian: Provjerite s liječnikom ako mislite da se to odnosi na Vas.
English: Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.
Croatian: Obavijestite svog liječnika ili ljekarnika ako neka nuspojava postane ozbiljna ili zabrinjavajuća ili primijetite neku nuspojavu koja nije navedena u ovoj uputi.
English: Lamivudine Teva Pharma B.V. does not completely cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level.
Croatian: Lamivudin Teva Pharma B.V. ne može potpuno izliječiti infekciju HIV-om; smanjuje količinu virusa u tijelu i održava je na niskoj razini.
English: Lamivudine is also available as an oral solution for children over three months of age and who weigh less than 14 kg or for patients who are unable to swallow tablets (see section 4.4).
Croatian: Lamivudin je dostupan i u obliku oralne otopine za djecu stariju od tri mjeseca i tjelesne težine manje od 14 kg ili za bolesnike koji ne mogu progutati tablete (vidjeti dio 4.4).
English: A 10 mg/mL oral solution may be the most appropriate formulation to achieve the recommended dose in children with renal impairment aged at least 3 months and weighing less than 25kg.
Croatian: Oralna otopina od 10 mg/ml mogla bi biti najprikladnija formulacija za postizanje preporučene doze u djece s oštećenjem bubrega u dobi od najmanje 3 mjeseca, čija je tjelesna težina manja od 25 kg.
English: • serious allergic reaction causing swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing
Croatian: • ozbiljne alergijske reakcije koje uzrokuju oticanje lica, jezika ili grla, što može izazvati teškoće s gutanjem ili disanjem • upala pankreasa (pankreatitis)
English: Co-administration of zidovudine results in a 13% increase in zidovudine exposure and a 28% increase in peak plasma levels.
Croatian: Istodobna primjena zidovudina dovodi do 13% veće izloženosti zidovudinu i 28% porasta vršnih razina u plazmi.
English: 20 film-coated tablets 30 film-coated tablets 60 film-coated tablets 80 film-coated tablets 90 film-coated tablets 100 film-coated tablets 500 film-coated tablets
Croatian: 20 filmom obloženih tableta 30 filmom obloženih tableta 60 filmom obloženih tableta 80 filmom obloženih tableta 90 filmom obloženih tableta 100 filmom obloženih tableta 500 filmom obloženih tableta
English: Other medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Croatian: Neki drugi lijekovi (npr. ranitidin, cimetidin) samo se djelomično izlučuju tim mehanizmom i ne ulaze u interakcije s lamivudinom.
English: The 300 mg tablet is only suitable for the once a day regimen.
Croatian: Tableta od 300 mg prikladna je samo za doziranje jedanput na dan.
English: Co-administration of lamivudine with food results in a delay of tmax and a lower Cmax (decreased by 47%).
Croatian: Istovremena primjena lamivudina s hranom odgađa tmax i smanjuje Cmax (smanjuje se do 47%).
English: Whenever possible in children, lamivudine as tablet formulation should preferably be used.
Croatian: Kad god je to moguće, kod djece treba dati prednost primjeni lamivudina u obliku tableta.
English: Children from three months of age: As an accurate dosage cannot be achieved with the 300 mg nonscored tablet formulation in this patient population, it is recommended that the Lamivudine Teva Pharma B.V. 150 mg scored tablet formulation is used and the corresponding recommended dosage instructions are followed.
Croatian: Djeca od navršena 3 mjeseca: Budući da se u ovoj populaciji bolesnika točna doza ne može postići tabletom od 300 mg bez razdjelnog ureza, preporučuje se koristiti Lamivudin Teva Pharma B.V. tabletu od 150 mg s razdjelnom crtom i slijediti odgovarajuće upute za preporučeno doziranje.
English: The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance (>70%) via the organic cationic transport system.
Croatian: Srednji sistemski klirens lamivudina je približno 0,32 l/h/kg, i odvija se pretežno renalnim klirensom (> 70%), putem organskog kationskog transportnog sustava.
English: The mean (CV) AUC over a dosing interval of 12 hours is 4.7 µg•h/ml (18%).
Croatian: Srednji AUC tijekom intervala doziranja od 12 sati je 4,7 µg.h/ml (18%).
English: The 150 mg tablet is bioequivalent and dose proportional to the 300 mg tablet with respect to AUC∞, Cmax, and tmax.
Croatian: Tableta od 150 mg je bioekvivalentna i proporcionalna dozi tablete od 300 mg s obzirom na AUC∞, Cmax i tmax.
English: Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Croatian: Nuspojave za koje se smatra da mogu biti povezane s liječenjem navedene su prema klasifikaciji organskih sustava i klasificirane prema učestalosti pojavljivanja kao: vrlo česte (≥ 1/10), česte (≥ 1/100 i < 1/10), manje česte (≥ 1/1000 i <1/100), rijetke (≥ 1/10 000 i < 1/1000), vrlo rijetke (<
English: When possible, avoid chronic coadministration of Lamivudine Teva Pharma B.V. with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol,
Croatian: Kada je moguće, izbjegavajte kroničnu istodobnu primjenu lijeka Lamivudine Teva Pharma B.V. s lijekovima koji sadrže sorbitol ili druge poliole osmotskog djelovanja ili monosaharidne alkohole (npr. ksilitol, manitol, laktitol,
English: The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim.
Croatian: Treba razmotriti moguće interakcije s drugim istodobno primijenjenim lijekovima, osobito onima čiji je glavni put eliminacije aktivna renalna sekrecija putem organskog kationskog transportnog sustava,
English: Very rare: Pure red cell aplasia.
Croatian: Vrlo rijetko: aplazija crvenih krvnih stanica
English: Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis should be avoided.
Croatian: Treba izbjegavati istodobnu primjenu lamivudina s visokim dozama kotrimoksazola u liječenju pneumonije uzrokovane Pneumocystis jirovecii (PIP) i toksoplazmoze.
English: The following adverse reactions have been reported during therapy for HIV disease with lamivudine:
Croatian: Sljedeće su nuspojave zabilježene tijekom liječenja HIV-infekcije lamivudinom:
English: do not stop Lamivudine Teva Pharma B.V. without your doctor's advice, as your hepatitis may come back)
Croatian: nemojte prestati uzimati Lamivudin Teva Pharma B.V. prije nego što Vam to savjetuje liječnik jer se hepatitis može vratiti)
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Immediate packaging (blister foil)
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Unutarnje pakiranje (blister)
English: Opportunistic infections: Patients receiving Lamivudine Teva Pharma B.V. or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with associated HIV diseases.
Croatian: Oportunističke infekcije: Bolesnici koji dobivaju Lamivudin Teva Pharma B.V. ili bilo koji drugi antiretrovirusni lijek mogu i dalje biti skloni razvoju oportunističkih infekcija kao i ostalih komplikacija infekcije HIV-om te stoga trebaju ostati pod strogim nadzorom liječnika s iskustvom u liječenju bolesti povezanih s HIV-om.
English: Keep in touch with your doctor, and do not stop taking Lamivudine Teva Pharma B.V. without your doctor's advice.
Croatian: Budite u kontaktu sa svojim liječnikom i nemojte prestati uzimati Lamivudin Teva Pharma B.V. ako Vam to nije savjetovao liječnik.
English: Lamivudine Teva Pharma B.V. helps to control your condition.
Croatian: Lamivudin Teva Pharma B.V. pomaže u kontroli Vašeg stanja.
English: If you or your child has a kidney problem, your dose may be altered.
Croatian: Ako Vi ili Vaše dijete imate problema s bubrezima, može biti potrebno promijeniti dozu.
English: Read the information ‘Other possible side effects of combination therapy for HIV' in section 4 of this leaflet.
Croatian: Pročitajte „Druge moguće nuspojave kombinirane terapije za bolesnike s HIV-om“ u dijelu 4
English: This conclusion is based on the physicochemical and pharmacokinetic data assuming that the patient crushes and transfers 100% of the tablet and ingests immediately.
Croatian: Ti se zaključci temelje na fizikalno-kemijskim i farmakokinetičkim podacima, ali pod pretpostavkom da je bolesnik u potpunosti i odmah uzeo usitnjeni pripravak.
English: Lamivudine metabolism does not involve CYP3A, making interactions with medicinal products metabolised by this system (e.g. PIs) unlikely.
Croatian: Metabolizam lamivudina ne uključuje enzim CYP3A te stoga nisu vjerojatne interakcije s lijekovima koji se metaboliziraju putem tog sustava (npr. inhibitori proteaze).
English: Lamivudine at a dose of 100 mg once daily has also been shown to be effective for the treatment of adult patients with chronic HBV infection (for details of clinical studies, see the prescribing information for lamivudine 100 mg).
Croatian: Lamivudin u dozi od 100 mg jedanput na dan pokazao se djelotvornim u liječenju odraslih bolesnika s kroničnom hepatitis B infekcijom (za detalje o kliničkim ispitivanjima, vidjeti upute za propisivanje lamivudina 100 mg).
English: Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin (<16%-36% to serum albumin in in vitro studies).
Croatian: U terapijskom rasponu doziranja lamivudin ima linearnu farmakokinetiku i slabo se veže na albumin, glavnu bjelančevinu u plazmi (<16 - 36% na serumski albumin u in vitro ispitivanjima).
English: Lamivudine Teva Pharma B.V. can be used during pregnancy if clinically needed.
Croatian: Lamivudin Teva Pharma B.V. se može primjenjivati u trudnoći samo ako je to klinički potrebno.
English: People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections).
Croatian: Stare infekcije mogu se razbuktati Ljudi s uznapredovalom HIV-infekcijom (SIDA) imaju oslabljen imunološki sustav i skloniji su razvoju ozbiljnih infekcija (oportunističkih infekcija).
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis jirovecii pneumonia (often referred to as PCP).
Croatian: Relevantni primjeri uključuju citomegalovirusom izazvani retinitis, generalizirane i/ili fokalne infekcije mikobakterijama i pneumoniju izazvanu s Pneumocystis jirovecii (često se nazia PIP).
English: This does not require dose adjustment unless the patient also has renal impairment (see sections 4.5 and 4.2).
Croatian: To ne zahtijeva prilagodbu doze ako bolesnik ne pati od oštećenja bubrežne funkcije (vidjeti dio 4.5. i 4.2).
English: Treatment with Lamivudine Teva Pharma B.V. should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur.
Croatian: Primjenu lijeka Lamivudin Teva Pharma B.V. treba odmah prekinuti ako nastupe klinički znaci, simptomi ili poremećaji laboratorijskih vrijednosti koje upućuju na pankreatitis.
English: If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor about the risks and benefits to you and your baby of taking Lamivudine Teva Pharma B.V.. Lamivudine Teva Pharma B.V. and similar medicines may cause side effects in unborn babies.
Croatian: Ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete, razgovarajte sa svojim liječnikom o rizicima i prednostima uzimanja lijeka Lamivudin Teva Pharma B.V. za Vas i Vaše dijete.
English: Once daily dosing (300 mg once a day): a clinical study has demonstrated the non-inferiority between lamivudine once a day and lamivudine twice a day containing regimens.
Croatian: Doziranje jednom na dan (300 mg jedanput na dan): kliničko je ispitivanje pokazalo da primjena lamivudina jedanput na dan nije inferiorna primjeni dvaput na dan.
English: 6.5 Nature and contents of container
Croatian: 6.5 Vrsta i sadržaj spremnika Blisteri